Omicron变异株研究进展

摘要/Abstract

摘要： 新型冠状病毒肺炎(Coronavirus disease 2019, COVID-19),简称“新冠肺炎”,是由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)引起的急性呼吸道传染病。SARS-CoV-2的变异株中,有些表现出高传染性、免疫逃逸等特性,这些变异株被归为“需要关注的变异株”(variants of concern, VOC)。2021年11月新发现的omicron变异株是目前第五种VOC,其突变数量众多,传染性大幅增强,能够逃逸中和抗体,而致病性似乎有所减弱。本文就omicron的突变及其潜在的功能与特性的改变作一简要综述。

关键词: SARS-CoV-2, Omicron, 突变, 刺突蛋白, 免疫逃逸

陈曜星, 赖荣陶, 谢青. Omicron变异株研究进展[J]. 肝脏, 2022, 27(4): 401-404.

参考文献

[1] Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020, 181: 281-292.e286.
[2] Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell, 2022, 185: 447-456.e411.
[3] Maslo C, Friedland R, Toubkin M, et al. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. JAMA, 2022, 327: 583-584.
[4] Cele S, Karim F, Lustig G, et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe, 2022, 30: 154-162.e155.
[5] Wei C, Shan KJ, Wang W, et al. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. J Genet Genomics, 2021, 48: 1111-1121.
[6] Benvenuto D, Angeletti S, Giovanetti M, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. J Infect, 2020, 81: e24-e27.
[7] Hillen HS, Kokic G, Farnung L, et al. Structure of replicating SARS-CoV-2 polymerase. Nature, 2020, 584: 154-156.
[8] De Silva TI, Liu G, Lindsey BB, et al. The impact of viral mutations on recognition by SARS-CoV-2 specific T?cells. iScience, 2021, 24: 103353.
[9] Leary S, Gaudieri S, Parker MD, et al. Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. Pathog Immun, 2021, 6: 27-49.
[10] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 181: 271-280.e278.
[11] Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science, 2022, 375: 760-764.
[12] Hui KPY, Ho JCW, Cheung M-C, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature, 2022, 603: 715-720.
[13] Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603: 706-714.
[14] Meng B, Kemp SA, Papa G, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep, 2021, 35: 109292.
[15] Brown KA, Gubbay J, Hopkins J, et al. S-gene target failure as a marker of variant B. 1.1. 7 among SARS-CoV-2 isolates in the greater Toronto area, December 2020 to March 2021. JAMA, 2021, 325: 2115-2116.
[16] Kannan SR, Spratt AN, Sharma K, et al. Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies. Journal of Autoimmunity, 2022, 126: 102779.
[17] Chen J, Wang R, Gilby NB, et al. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model, 2022, 62: 412-422.
[18] Huang J, Zeng G. Epidemiology of the SARS-CoV-2 variant Omicron BA. 2-vigilance needed. Eurosurveillance, 2022, 27: 22-00254.
[19] Grabowski F, Kochańczyk M, Lipniacki T. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion. Viruses, 2022, 14: 294.
[20] UK Health Security Agency. Investigation of SARS-CoV-2 variants: technical briefings. https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings.
[21] Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med, 2020, 26: 681-687.
[22] Shuai H, Chan JF-W, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature, 2022, 603: 693-699.
[23] Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet,2022,399(10335):1618-1624.
[24] Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature, 2022, 602: 657-663.
[25] Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N Engl J Med, 2022, 386: 599-601.
[26] Sokal A, Broketa M, Barba-Spaeth G, et al. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. Immunity, 2022.
[27] Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell, 2022, 185: 847-859.e811.
[28] Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med, 2022, 28: 477-480.
[29] Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med, 2022, 386: 1046-1057.
[30] Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B. 1.1. 529) variant. N Engl J Med, 2022,386(16):1532-1546.
[31] Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 2022, 604: 553-556.
[32] Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature, 2022, 602: 671-675.
[33] Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect, 2022, 11: 277-283.
[34] Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. N Engl J Med, 2022, 386: 995-998.